相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- Apple Health app users in the U.S. will be able to purchase a Quest Diagnostics lab panel covering over 50 biomarkers directly through the app on iPhone and iPad later this year. - The panel assesses cardiometabolic health and organ function, and includes biometric readings such as blood pressure, height, weight, and waist and hip circumferences. - Users can schedule blood draws and biometric readings at one of Quest's roughly 2,000 U.S. patient service centers for $119, with results delivered in the Apple Health app. - Quest collaborates with third-party providers to review and approve test orders and, at the user's request, discuss results and next steps at no additional charge.
- Humanity Health Inc. and Quest Diagnostics have launched Humanity Biological Age, a scientifically validated biological age measurement, in the U.S. for the first time through questhealth.com. - The add-on costs $29 and requires no additional blood draw, integrating with select Quest health profile tests at approximately 2,000 patient service centers nationwide. - The model was developed with Imperial College London and trained on more than 306,000 UK Biobank participants followed for an average of 11.6 years, with validation on a separate cohort. - The report identifies which body systems influence biological age, including cardiovascular, metabolic, liver, kidney, blood, immune, hormonal, and bone and mineral health.
- Nearly one in five U.S. workers (19.1%) tested positive for drug use on hair specimens collected in 2025, up nearly 46% from 13.1% in 2021, according to the 2026 Quest Diagnostics Drug Testing Index. - Marijuana was the primary driver, accounting for 52.5% of hair drug positives, with hair-test positivity rising 58.9% over five years to 15.1% in 2025. - Year-over-year fentanyl positivity declined by nearly half (49.1%) in the general U.S. workforce, from 0.55% in 2024 to 0.28% in 2025. - Healthcare workers posted the highest overall drug positivity rate of any industry at 5.8%, while retail trade had the highest marijuana positivity at 7.6%.
- Attunio Health selected Quest Diagnostics as its national laboratory backbone and integrated Getlabs for at-home blood collection just days after its public launch. - The platform merges AI-driven clinical insights, wearable physiological data, blood biomarker analysis, genetic testing, and behavioral observation into a "Closed-Loop Precision Psychiatry" model. - Diagnostic capabilities help clinicians identify biological contributors to mental health impairment including metabolic dysfunction, inflammation, nutritional deficiencies, and hormonal imbalances. - The infrastructure aims to make biomarker-driven psychiatric care more accessible nationwide by enabling certified mobile phlebotomists to collect specimens at patients' homes or workplaces.
- City of Hope is implementing Quest Diagnostics' Haystack MRD circulating tumor DNA test in a multi-year research program across 14 sites to guide patient management in breast, colorectal, ovarian, and prostate cancers. - The clinical trials will evaluate approximately 500 patients with thousands of longitudinal measurements to assess the test's ability to detect minimal residual disease, monitor treatment response, and identify recurrence earlier than standard imaging. - The research spans multiple patient management settings including neoadjuvant, adjuvant, and post-treatment surveillance, with the potential to help determine surgical success and spare unnecessary chemotherapy treatments. - Haystack MRD received FDA Breakthrough Device Designation in 2025 for Stage II colorectal cancer, and 96% of oncologists surveyed believe MRD testing can identify cancer recurrence earlier than current methods.
- The prospective CLiMB study demonstrated that HelioLiver, a multi-analyte blood test, achieved 47.8% sensitivity for overall HCC detection compared to 28.3% for ultrasound surveillance in patients with cirrhosis. - The blood-based test showed particularly strong performance for early-stage disease, detecting 40.0% of T1/stage 1 HCC cases versus only 10.0% for ultrasound, and 28.6% versus 0% for lesions smaller than 2 cm. - HelioLiver maintained statistical non-inferior specificity at 87.6% compared to ultrasound's 93.9%, while addressing critical surveillance gaps as only 9% of cirrhosis patients currently receive recommended semiannual ultrasound screening. - The test combines cell-free DNA methylation patterns, protein biomarkers, and patient demographics using AI algorithms, and is now commercially available through Helio Genomics' partnership with Quest Diagnostics.
- Guardant Health announced a strategic partnership with Quest Diagnostics to integrate Shield colorectal cancer screening into Quest's EMR network, reaching approximately 650,000 physicians and adding co-promotion capabilities. - The company expects FDA approval for Guardant360 in the second half of 2025, which is viewed as a major catalyst with potential ADLT repricing finalization in early 2027 and current ASP of about $3,100. - Shield CRC screening targets a 54 million patient opportunity with 90% of patients not screened in five years, while Reveal MRD represents the company's fastest-growing oncology product. - Management projects achieving cash flow breakeven by end of 2027 through revenue growth drivers including expanded clinical applications, repeat testing, and a salesforce expansion from 100 to 300 representatives.
- Quest Diagnostics has launched the Quest Flow Cytometry MRD for Myeloma test, a noninvasive blood-based alternative to traditional bone marrow biopsies for monitoring residual disease in multiple myeloma patients. - The test provides sensitivity comparable to next-generation sequencing methods while offering improved specimen stability of five days compared to conventional flow cytometry's three-day window. - The launch aligns with FDA draft guidance issued in January 2026 that supports using measurable residual disease as a primary endpoint in clinical trials for multiple myeloma treatments. - Quest's extensive network of approximately 7,000 phlebotomy sites across the United States will enable widespread access to this monitoring tool for cancer patients managing myeloma as a chronic condition.
- Visby Medical has partnered with Quest Diagnostics and Labcorp to expand national access to the first FDA-authorized at-home PCR test for sexually transmitted infections, delivering lab-quality results in 30 minutes. - The palm-sized device tests for chlamydia, gonorrhea, and trichomoniasis, addressing the urgent need for accessible STI testing as nearly 100,000 women lose fertility annually due to untreated infections. - The test is now available through questhealth.com and Labcorp OnDemand, complementing existing partnerships with Everlywell, DoorDash, and GoPuff for nationwide distribution. - The integrated "Test-to-Treat" ecosystem enables same-day virtual care and medication access, potentially moving patients from diagnosis to treatment within a single day.
- Exact Sciences has launched Cancerguard, the first commercially available multi-cancer early detection blood test that analyzes multiple biomarker classes to detect over 50 cancer types. - The $689 test demonstrated 68% sensitivity across six of the deadliest cancers and 97.4% specificity in studies involving more than 20,000 participants. - Cancerguard addresses a critical gap by targeting the 70% of annual U.S. cancer cases that lack recommended screening protocols, including pancreatic, ovarian, and liver cancers. - The test is available through Quest Diagnostics' 7,000 patient access sites nationwide and is recommended for annual screening in adults aged 50-84.
